Life Sciences

  InMed Pharmaceuticals Inc. (CNSX:IN) (OTCMKTS:IMLFF) (FRA:MWG2) performs research on extracted and purified cannabinoids to treat severe disease. President and CEO Eric Adams talks to James about the Canadian cannabinoid market, patenting, and [...]
Michelle-Andrea Girouard

Stephen Goldner is the co-inventor of the liquid formulation of methadone, the only real option in the treatment of opioid addictions currently in wide use. Dr. Goldner has created a new line of [...]
James West


Sorry, no Videos to show. Please check back later


PODCAST: Myomo Inc. CEO Paul Gudonis on becoming the First Reg A+ IPO to list on NYSE MKT

James West

Myomo Inc is a medical robotics company based in Cambridge, MT is a developer of next-generation orthotics that include “powered braces” that support impaired hands and arms. The company has raised over US$20 million via Regulation A+, which, for those who don’t know, enables companies like Myomo to raise millions of dollars from individual investors without giving away the company to an investment bank. They will become the first company to list on the NYSE MKT via IPO using Regulation […]

Knight Therapeutics CEO Jonathan Goodman Interview Podcast

James West

Knight Therapeutics (TSE:GUD) CEO Jonathan Goodman discusses his company’s strategy of acquiring already licensed drugs and pharmaceuticals and bringing them to Canada for the benefit of Canadians. Transcript: James West:   Jonathan, thank you for joining us today. Jonathan Goodman:    Thank you. Thank you for having me. James West:    Jonathan, could you please outline very generally what is the business model and opportunity for investors in Knight Therapeutics, please? Jonathan Goodman:    We want to become Canada’s leading specialty pharmaceutical company. We […]

PediaPharm Inc. CEO Sylvain Chretien Interview Podcast

James West

PediaPharm Inc. CEO Sylvain Chretien discusses his company’s licensing agreement with Roche Holding Ltd. (VTX:ROG), as well as the features of the business model that have attracted marquis investors such as  Senvest Capital Inc. (TSE:SEC), Knight Therapeutics Inc. (TSE:GUD), and  Bloom Burton. James West: Sylvain your company recently touched a 52-week high in the shares of Pedipharm. Can you give me an overview of what the value proposition is for investors in Pediapharm and what has been catalyzing such excellent performance in […]

Sign up for our free newsletter

and get more of MidasLetter delivered to your inbox.

Receive With your NEW subscription

Free and immediate access to these three recently published special reports